Global pharmaceutical mergers have spread the huge costs of research and enabled companies to sell their products in countries where they previously lacked a presence. Here's how the Beecham-SmithKline Beckman mar...
详细信息
Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.
Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.
Major resource-allocation decisions are never easy. For a pharmaceuticals company like Smith Kline Beecham, the problem is this: How do you make good decisions in a high-risk, technically complex business when the inf...
详细信息
Major resource-allocation decisions are never easy. For a pharmaceuticals company like Smith Kline Beecham, the problem is this: How do you make good decisions in a high-risk, technically complex business when the information you need to make those decisions comes largely from the project champions who are competing against one another for resources? In 1993, the company experimented with ways of depoliticizing the process and improving the quality of decision making. In most resource-allocation processes, project advocates develop a single plan of action and present it as the only viable approach. In SB's new process, the company found an effective way to get around the all-or-nothing thinking that only reinforces the project-champion culture. Project teams were required-and helped-to create meaningful alternatives to current development plans. What would they do with more money? With less? With none at all? In another important departure from common practice, SE separated the discussion of project alternatives from their financial evaluations. In doing so, SE was able to avoid the premature evaluations that kill both creativity and the opportunity to improve decision making. The new process at SE has allowed the organization to spend less time arguing about how to value its R&D projects and more time figuring out how to make them more valuable. In the end, the company learned that by tackling the soft issues around resource allocation-such as information quality, credibility, and trust-it had also addressed the hard ones: how much to invest and where to invest it.
Focuses on the business alliance between Cambridge, Massachusetts-based Millennium and Frankfurt, Germany-based Aventis Pharma Ltd., the pharmaceutical division of Aventis SA to develop and market drugs to treat infla...
详细信息
Focuses on the business alliance between Cambridge, Massachusetts-based Millennium and Frankfurt, Germany-based Aventis Pharma Ltd., the pharmaceutical division of Aventis SA to develop and market drugs to treat inflammatory conditions. Benefits of the business alliance; Amount of the deal; Plans of the companies.
The merger of Glaxo Wellcome and SmithKline Beecham will create a pharmaceutical giant which may rank number one in the world in terms of spending on research and development.
The merger of Glaxo Wellcome and SmithKline Beecham will create a pharmaceutical giant which may rank number one in the world in terms of spending on research and development.
Focuses on the success of Oxford, England-based British Biotech PLC in reducing its annual losses. Amount of the loses saved by the company; Products produced by the company; Future plans of the company.
Focuses on the success of Oxford, England-based British Biotech PLC in reducing its annual losses. Amount of the loses saved by the company; Products produced by the company; Future plans of the company.
Presents a response to the News Focus article `Drug research endures the pains of globalization,' by Joanna Rose and Annika Nilsson, about the inaccuracies regarding the research and development strategy of AstraZ...
详细信息
Presents a response to the News Focus article `Drug research endures the pains of globalization,' by Joanna Rose and Annika Nilsson, about the inaccuracies regarding the research and development strategy of AstraZeneca in Sweden. Location of the research and development headquarters of AstraZeneca; Correction regarding the location of the company's cancer research.
暂无评论